2025

• Thomas Sauer and Daniel Degreif, Microbial Platform USP Development, Sanofi R&D
  Tuned Microbial Expression Systems for Highly Engineered Biologics
  April 4th, 2025

• James Piret, Professor in Chemical and Biological Engineering, Michael Smith Laboratories, University of British Columbia, Canada
  Process Analytical Utility of Raman Microscopy for Cell Therapy Manufacturing
  March 17th, 2025

• Qasim Rafiq, Vice Dean for Health Faculty of Engineering Sciences and Director of UCL Institute of Healthcare Engineering, University College London, UK
  Process Intensification and Adaptive Manufacturing Strategies for ATMPs
  February 26th, 2025

• Elisabetta Traggiai, Executive Director Immunogenicity & Mechanistic Immunology Unit, Biologics Research Center, Novartis Institute for Biomedical Research, Switzerland
  A Patient Immune Journey: from Immune Memory to Target Identification and Biotherapeutic Design
  February 11th, 2025

• Eric Kremer, Head of Adenovirus - Receptors, Trafficking, Immunogeneicity & Vectorology Lab, Institut de Génétique Moléculaire de Montpellier (igmm), Montpellier, France
  Comprehensive Dravet Syndrome Therapy by Canine Adenovirus (CAV-2)-mediated Expression of NaV1.1
  January 10th, 2025

2024

• Diana Schenkwein, Senior Researcher, AI Virtanen Institute for Molecular Sciences, University of Eastern Finland
  On a Mission to Enable New Gene Therapies for Currently Uncurable Diseases: Pushing the Boundaries of Lentiviral Vectors
  November 5th, 2024

• Ana M Carrion, Associate Director, Bioanalytics and Formulations, Novartis
  Example of a Bioanalytical Strategy to Identify Lead Antibody Candidates
  October 30th, 2024 

• Matti Korhonen, Senior Medical Officer, Research and Development Finnish Red Cross Blood Service, Finland
  Development of Novel CAR T and CAR NK-cells for Hematological and Solid Tumors
  October 17th, 2024 

• Alain Bernard, Founder and General Manager of BAPC Consulting
  The story of a Biotech Startup Bringing Innovation to Market
  October 8th, 2024 

• Elizabeth Anderson, Director of Pharmacology and Cancer Drug Discovery, STORM Therapeutics Limited, Cambridge, UK
  Experience and Highlights in a Cancer Research Career
  May 6th, 2024 

• Evren Alici, Head of Cell and Gene Therapy Research Group and Head of Multiple Myeloma Programme, Karolinska Institutet, Sweden
  Natural Killer Cells in Cancer: From Discovery to Clinical Applications
  February 15th, 2024 

• Catarina Palma dos Reis, Resident in Obstetrics and Gynecology, Maternidade Alfredo da Costa - Lisbon and DPhil Candidate, Oxford, UK
  Syncytiotrophoblast-derived Extracellular Vesicles in Fetal Growth Restriction
  January 4th, 2024 

2023

• Dagmar Wirth, Head of the Model Systems for Infection and Immunity (MSYS) Research Group at Helmholtz Centre for Infection Research (HZI), Germany
  Strategies for Autonomously Controlled Responses to Infections by Engineered Therapeutic Cells
  July 19th, 2023 

• Yonghyun (John) Kim, Associate Professor of Chemical and Biological Engineering, University of Alabama, USA
  Bioengineering of Cancer Stem Cells for Improved 3D Cell Models and Disease Modeling
  March 27th, 2023 

• Isabelle Bekeredjian-Ding, Head of the Microbiology Division and acting Director of the Center for Pandemic Vaccines and Therapeutics at Paul-Ehrich Institut
  Vaccine Development Against Antibiotic Resistant Pathogens
  February 7th, 2023 

2022

• John G. Aunins, Executive VP of Bioprocess & Manufacturing and Chief Technology Officer, Seres Therapeutics
  Development of Live Bacterial Therapeutics
  April 8th, 2022 

2021

• Luís Maranga, Global Head of MSAT, Sanofi Genzyme
  Innovation in post licensure manufacturing enabled through process intensification and advanced biologics characterization
  March 3rd, 2021 

2020

• José (Joe) Santos
  Innovation: Composing Across Confines
  March 16th, 2020 

2019

• Brandon DeKosky
  Large-scale functional analysis of natively paired antibody heavy light chain repertoires
  November 20th, 2019
• José Manuel Otero
  Disruptive engineering of viral immunotherapies to create a world free of cancer
  October 23rd, 2019
• Renata Stripecke
  Re-Generando: Gene modified dendritic cells and CAR-T cells to rebuild the immune system
  October 8th, 2019
• Harald Dinter
  Challenges of the pharmaceutical industry and its implications for collaborators
  May 13th, 2019
• Joost Sluijter
  Therapeutics for myocardial repair – moving forward?
  September 14th, 2018

2018

• Jörg Weiske, Head of Protein Technologies 1, Research & Development, Pharmaceuticals at Bayer AG
  Cellular Thermal Shift Assay (CETSA) - Case study @ Protein Technologies (Bayer AG)
  May 17th, 2018
• Tom L. Blundell, Cambridge University, UK
  Structure-guided Fragment-based Drug Discovery for Cancer and Tuberculosis: Fighting the Emergence of Resistance
• Alois Jungbauer, Department of Biotechnology, BOKU, Vienna, Austria
  Separation and Quantification of Virus-like Particles from other extra cellular particles
  March 15th, 2018
• David Naveh, Ph.D., MBA, CEO Hemogem, ex- VP and ex-CTO of Bayer Biological Products Worldwide
  Development of Biological Therapeutics for Health and Financial Value Creation - The Pharma Perspective
  March 7th, 2018
• Monique M. van Oers, Laboratory of Virology, Wagninngen University, the Netherlands
  Proteins Required for Baculovirus Particle Formation: Relevance for the Development of a Baculovirion-Free Expression System
  March 7th, 2018
• Mike Betenbaugh, Johns Hopkins University, USA
  Glycoengineering in CHO cells: Glyco Control-Inside and Out
  February 5th, 2018
• Andreas Busch, Head of Drug Discovery - Bayer Pharmaceuticals
  Addressing unmet medical needs: Key drivers for Drug Discovery at Bayer
  January 8th, 2018
• Manel Cascalló, VCN Biosciences SL, Spain
  Oncolytic adenoviruses expressing hyaluronidase: from bench to patients
  January 8th, 2018
• Eda Machado, St. Jude Children's Research Hospital, Memphis, Memphis, Tennessee USA
  Regulated lysosomal exocytosis, an unconventional pathway in cancer progression
  January 8th, 2018
• Andreas Wilmen, Protein Engineering & Assays 2, Bayer AG
  Cardiovascular Research at Bayer
  January 8th, 2018
• Hansjörg Hauser, Department of Scientific Strategy, Helmholtz Centre for Infection Research (HZI)
  Viral defence by interferons: A closer look to single cells in populations
  January 8th, 2018

2017

• William M. Miller, Chemical and Biological Engineering, Northwestern University Evanston, USA
  A Uniform-Shear-Rate Microfluidic Bioreactor for Real-Time Analysis of Proplatelet Formation and Rapidly-Released Platelets
  June 21st, 2017
• Alain Bernard, Biopharma Executive Advisor, Independent advisor to pharma executives · Institut National Agronomique Paris-Grignon
  Knowledge Management
  April 12th, 2017
• Felipe Prosper, Director of Hematology and Cell Therapy, Clinica Universidad de Navarra
  Drug and cell delivery systems for cardiac repair
  February 7th, 2017
• Simone Kardinahl, Head of Cell & Protein Sciences, Biologics Research, Bayer AG
  DD Biologics – an overview on challenges and opportunities
  January 31st, 2017

2016

• Brian Murphy, Celgene Cellular Therapeutics, USA
  Quality by Design and Phase Appropriate Development for Cell Therapies
  November 28th, 2016
• Thorsten Lorenz, Novartis Pharma AG, Basel, Switzerland
  Developability Assessment of therapeutic Antibodies - A concept for early Lead Selection
  May 31st, 2016
• Katey Owen, Deputy Director for Vaccines Development (CMC), Bill & Melinda Gates Foundation
  Vaccine development and manufacturing for those most in need of vaccines
  April 29th, 2016

2015

• Philippe Couttet, Novartis Institutes of Biomedical Research in Basel, Switzerland
  microRNAs as biomarker of drug-induced tissue injury
  December 3rd, 2015
• Uwe Marx, CEO, TissUse GmbH
  Humans-on-a-chip” – a paradigm shift in substance testing?!
  November 17th, 2015
• Eytan Abraham, Head of Cell Therapy Research & Technology, Lonza, USA
  Stem Cells and Cell Therapy at LONZA
  July 13th, 2015
• Hitto Kaufmann, Vice President Technology and Development at Sanofi Biologics, Germany
  Innovation in Biologics Manufacturing
  May 27th, 2015
• Thomas Pietzonka, NIBR Biologics Center, Basel
  Changing the Practice of Medicine - Novartis Institutes for Biomedical Research
  May 4th, 2015
• Matthias Frech, MERCK KGaA
  Biophysical Methods in Drug Discovery: Combination is Key. The Project Kinetics for Drug Discovery
  February 27th, 2015
• Roger-Marc Nicoud, NOVASEP HOLDING S.A.S., FRANCE
  The amazing ability of continuous chromatography to adapt to a moving environment
  February 12th, 2015

2014

• Carlos Augusto Pereira, Instituto Butantan, Laboratorio de Imunologia Viral, São Paulo, Brazil
  Vectors carrying heterologous RNA for designing new viral vaccines
  October 23rd, 2014
• Christof von Kalle, MD, PhD, National Center for Tumor Diseases (NCT), Heidelberg
  Translational Oncology – the National Center for Tumor Diseases
  October 17th, 2014
• Rene Hoet, Heiner Apeler, Lars Linden, Beate Müller-Tiemann, BAYER HEALTHCARE, Global Biologics, Germany
  Protein Biopharmaceuticals @ Bayer: From Discovery to Development
  July 3rd, 2014
• Vish Nene, THE INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE (ILRI), NAIROBI - KENYA
  The ILRI Vaccine Biosciences program and improved vaccines for the control of East Coast fever in cattle
  May 16th, 2014

2013

• Marc Peschanski, I-STEM (INSERM/UEVE 861, AFM), Evry – France
  Harnessing pluripotent stem cells for pharmacology
  July 18th, 2013

2012

• Muntasir Mamun Majumder, FIMM, Institute for Molecular Medicine Finland
  An individualized system medicine platform to guide treatment decisions for therapy-resistant Acute Myeloid Leukemia
  June 21st, 2012
• Joachim Klein, Technische Universtat Braunschweig, Germany (jUb.), President, Braunschweig Academy of Sciences, Germany
  Not all chemicals are created equal: The potential of biobased processes and products
  June 1st, 2012

2011

• John G. Aunins, Visiting Professor, ITQB, Merck Sharp & Dohme, West Point, New Jersey, USA
  Some Perspectives on Vaccines, Biologicals, and the Pharmaceutical Industry
  November 15th, 2011
• Uwe Marx & Mark Rosowski, Technische Universität Berlin, Institute of Biotechnology - Department of Medical Biotechnology
  Vascularized multi-organ systems – the next level of engineering human biology in vitro
  August 4th, 2011
• Isabelle Knott, Director, Head of Cell Culture Development, GlaxoSmithKline Biologicals S.A., Rixensart, Belgium
  Cervarix: first human vaccine manufactured with baculovirus expression system
  July 12th, 2011
• Héla Kallel, Head, Bioprocess Development Unit, Institut Pasteur de Tunis
  Bioprocess development activities at Institut Pasteur of Tunis
  June 28th, 2011
• Regina Grillari, PhD, Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria
  The importance of peeing earnest: urine derived cells as model systems in biology and biomedicine
  June 17th, 2011
• Christian Manzke & Etienne Evrard MD, Sartorius Stedim Biotech GmbH – B. Braun AG -Goettingen / Melsungen
  Bioprocess integrated solutions
  Abril 27th, 2011
• Brian Lee MD, President, PBS Biotech, Inc, California, EUA
  Mixing methodologies in single use bioreactors - A comparative analysis of consistency across scale
  Abril 4th, 2011
• Aleš Štrancar MD PhD, BIA Separations, Ljubljana
  Monolithic chromatography supports – technology platform for the analysis and production of new generation of drug candidates like plasmid DNA and viral vector particles
  March 21st, 2011
• Wilfried Bakker MD, Netherlands Vaccine Institute (NVI/RIVM)
  Development and Technology Transfer for Viral Vaccines
  March 15th, 2011
• Leo van der Pol MD PhD, Netherlands Vaccine Institute (NVI/RIVM)
  Overview of Vaccine Process Development at RIVM
  March 15th, 2011
• Marc Peschanski MD, Scientific Director, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-STEM, INSERM/UEVE) Evry, France
  Pathological modeling, drug discovery and toxicity testing using pluripotent stem cells
  March 2nd, 2011
• Leo van der Pol MD
  Overview of Vaccine Process Development at RIVM
  2011

2010

• Nigel Jenkins, National Institute for Cellular Biotechnology, Ireland
  Quality considerations for the production of biopharmaceuticals
  February 2nd, 2010
• Hagen von Briesen, Fraunhofer-Institute for Biomedical Engineering
  Global HIV Vaccine Research Cryorepository - GHRC
  January 29th, 2010

2009

• Judy Lieberman, Immune Disease Institute and Program in Cellular and Molecular Medicine, Children’s Hospital Boston, Dept of Pediatrics, Harvard Medical School
  Micromanaging cell growth and differentiation
  December 16th, 2009
• Octavio T. Ramírez, Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología Universidad Nacional Autónoma de México
  Bioreactor Scale-Down Studies of Temperature-Inducible Recombinant Protein Production in E. coli
  November 23th, 2009
• Kenneth Lundstrom, PanTherapeutics, Lausanne, Switzerland
  Viral Vectors in Gene Therapy: Special Emphasis on Alphaviruses
  March 11th, 2009
• Kenneth Lundstrom, PanTherapeutics, Lausanne, Switzerland
  Expression of GPCRs in Drug Discovery and Structural Biology
  March 10th, 2009
• Catherine Brenner Jan, DR CNRS, Faculté de Pharmacie, Lausanne, Switzerland
  Signalisation et physiopathologie cardiaque INSERM U769
  February, 2009

2008

• Anna Price, In vitro Toxicology Unit,  European Centre for the Validation of Alternative Methods,  Institute of Health and Consumer Protection, European Commission Joint Research Centre, Ispra (VA), Italy
  Re-aggregated brain cell culture as a sensitive in vitro model to evaluate developmental/adult neurotoxicity: application for regulatory requirements
  October 28th, 2008
• Dr. Ing. Reiner Luttmann, Hamburg University of Applied Sciences, Research Center of Bioprocess Engineering and Analytical Techniques
  A comprehensive study in optimal production of Active Pharmaceutical Ingredients with Pichia pastoris
  September 12th, 2008
• Manuel Cánovas, Department of Biochemistry and Molecular Biology B. Faculty of Chemistry. University of Murcia
  Bioprocess Optimization By Using Systems Biology
  September 11th, 2008
• Matthew Croughan, Amgen Bioprocessing Center, Keck Graduate Institute (KGI), Claremont, CA
  The Silver Anniversary of Clinical Protein Production from Recombinant CHO Cell Culture
  June 9th, 2008

Other presentations

• Carlos A. Pereira, Univ. Strasbourg, França and Instituto Butantan, Brasil
  Approaches for preparation of viral antigens from mammalian and insect cells
• John Aunins, MERCK & CO, Philadelphia, EUA and ITQB/UNL, Portugal
  Adenovirus-vectored HIV vaccine development
• Hansjörg Hauser, GBF and Univ. Braunschweig, Germany
  Cancer immune therapy using genetically modified dendritic cells
• Eric J. Kremer, CNRS-UMR, France
• Ursula Sonnewald, Pharmacology & Toxicology Medical School Trondheim, Norway
• Uwe Gottschalk, Sartorius AG, Germany
• Heiko Zimmermann, Fraunhofer IBMT, Germany
• Catherine Brenner, CNRS-UMR, France
• Kenneth Lundstrom, PanTherapeutics, Switzerland
• Brian Kelley, Genentech, USA
• Laura Palomares, México